Is a COVID-19 treatment drug for the unvaccinated underway?


COVID-19 treatment drug discovery and development: Can Molnupiravir effectively protect the unvaccinated?


COVID-19 Disease Prevention and Control for Healthy Living

Public Health care Education


Image credit:


Is a household COVID-19 treatment drug, Molnupiravir, for the unvaccinated underway?


Good news might be awaiting many COVID-19 unvaccinated people are in great expectation for a COVID-19 treatment drug breakthrough, according to a media report.

In another welcome move to COVID-19 disease prevention and control for a healthier living, a handful of patients are being recruited in Hampton Roads via medical practice for a clinical trial to study a new drug, Molnupiravir, that could stop people from contracting the coronavirus (COVID-19) from others in their homes. Several drugmakers are testing other medications for the treatment of COVID-19 now

The clinical trial for Molnupiravir is aimed at protecting only completely unvaccinated people who share a household with someone known to have tested positive for COVID-19.

Coronavirus attaches to healthy cells in people’s bodies and multiply, but Molnupiravir is meant to cause a virus to make genetic copying mistakes to prevent it from reproducing – a secondary prevention measure that could help fight the virus off before it can get a hold of one’s body.

Doctors have stressed the need for antiviral medications that patients could take orally at the onset of symptoms to stop the coronavirus from advancing.

Tidewater Physicians Multispecialty Group is one of the dozens of locations around the world collecting data for the study of Molnupiravir, a new drug developed by Merck and Ridgeback Biotherapeutics, according to the report.

On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved Veklury (Remdesivir) for use in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization, though it was rejected by World Health Organization (WHO). The approved COVID-19 antiviral drug — Remdesivir — in the US, authorized the use of three antibody therapies that help the immune system kick the virus. But all the drugs have to be given intravenously at hospitals or health care facilities.

Read more on The Virginia-Post


In other Eduonwheels’ COVID-19 Pandemic Disease Prevention and Control for Healthier Living that might interest you

US approves COVID-19 treatment drug

Black and pink contaminants found in COVID-19 vaccines

Alternative plasma-derived therapy treatment to COVID-19 vaccines, on the way 

5 COVID-19 Delta Variant Symptoms in Kids Revealed

Why COVID-19 Vaccine Booster Shot for Vaccinated people


This blog content on ‘COVID-19 Disease Prevention and Control: Is a household COVID-19 treatment drug, Molnupiravir, for the unvaccinated underway?’ is categorized under Public Health care Education.

Our Public Health care Education System is about creating and delivering impacting, and empowering problem-solving information towards enhancing prevention and control of COVID-19 spread to our amiable readers for better health and sustainable livelihood – Eduonwheels.


Submit a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This
Enable Notifications OK No thanks